The goal of PREVAIL 17 is to use existing specimens and data to further our understanding of the relationship between survival of Ebola virus disease (EVD) and eye disease, and to enroll individuals who participated in PREVAIL III into a new longitudinal cohort to understand long-term immunity to EVD from and long-term sequelae of infection.